Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVS NYSE:JNJ NYSE:NVO NYSE:TEVA NASDAQ:WBA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSCVS Health$93.240.0%$80.73$58.50▼$98.43$118.99B0.69.04 million shs4.84 million shsJNJJohnson & Johnson$234.67+0.1%$233.87$149.04▼$251.71$564.11B0.277.58 million shs5.46 million shsNVONovo Nordisk A/S$44.91-0.1%$40.43$35.12▼$81.44$200.75B0.7717.38 million shs10.77 million shsTEVATeva Pharmaceutical Industries$34.04-0.1%$31.92$14.99▼$37.35$39.17B0.867.65 million shs2.71 million shsWBAWalgreens Boots Alliance$11.98$11.89$10.90▼$12.25$10.37B0.814.58 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSCVS Health0.00%-2.82%+19.66%+21.09%+53.36%JNJJohnson & Johnson0.00%+3.47%+3.17%-4.42%+53.26%NVONovo Nordisk A/S0.00%+0.45%+9.02%+13.18%-33.23%TEVATeva Pharmaceutical Industries0.00%-0.73%+11.02%+0.37%+100.86%WBAWalgreens Boots Alliance0.00%0.00%0.00%0.00%+7.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSCVS Health$93.240.0%$80.73$58.50▼$98.43$118.99B0.69.04 million shs4.84 million shsJNJJohnson & Johnson$234.67+0.1%$233.87$149.04▼$251.71$564.11B0.277.58 million shs5.46 million shsNVONovo Nordisk A/S$44.91-0.1%$40.43$35.12▼$81.44$200.75B0.7717.38 million shs10.77 million shsTEVATeva Pharmaceutical Industries$34.04-0.1%$31.92$14.99▼$37.35$39.17B0.867.65 million shs2.71 million shsWBAWalgreens Boots Alliance$11.98$11.89$10.90▼$12.25$10.37B0.814.58 million shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSCVS Health0.00%-2.82%+19.66%+21.09%+53.36%JNJJohnson & Johnson0.00%+3.47%+3.17%-4.42%+53.26%NVONovo Nordisk A/S0.00%+0.45%+9.02%+13.18%-33.23%TEVATeva Pharmaceutical Industries0.00%-0.73%+11.02%+0.37%+100.86%WBAWalgreens Boots Alliance0.00%0.00%0.00%0.00%+7.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSCVS Health 2.85Moderate Buy$98.685.83% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.047.83% UpsideNVONovo Nordisk A/S 2.13Hold$65.5645.99% UpsideTEVATeva Pharmaceutical Industries 2.80Moderate Buy$41.7822.75% UpsideWBAWalgreens Boots Alliance 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest TEVA, JNJ, CVS, WBA, and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026CVSCVS Health MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$102.00 ➝ $110.005/14/2026CVSCVS Health ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $104.005/14/2026CVSCVS Health Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$93.00 ➝ $106.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/12/2026NVONovo Nordisk A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/12/2026CVSCVS Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$101.00 ➝ $111.005/12/2026CVSCVS Health Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$94.00 ➝ $106.005/11/2026CVSCVS Health TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$105.00 ➝ $110.005/11/2026CVSCVS Health TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$105.00 ➝ $110.005/8/2026CVSCVS Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSCVS Health$402.07B0.30$14.89 per share6.26$60.85 per share1.53JNJJohnson & Johnson$94.19B6.00$14.14 per share16.60$33.73 per share6.96NVONovo Nordisk A/S$46.80B4.28$4.68 per share9.59$7.12 per share6.31TEVATeva Pharmaceutical Industries$17.26B2.27$3.73 per share9.13$7.16 per share4.75WBAWalgreens Boots Alliance$147.66B0.07$5.73 per share2.09$13.91 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSCVS Health$1.77B$2.2741.0811.170.910.72%11.88%3.54%7/30/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6527.1318.652.2921.83%32.60%13.29%7/15/2026 (Estimated)NVONovo Nordisk A/S$15.51B$4.2610.5413.054.0137.23%63.31%22.19%8/5/2026 (Estimated)TEVATeva Pharmaceutical Industries$1.41B$1.3325.5911.203.299.01%43.53%8.19%7/29/2026 (Estimated)WBAWalgreens Boots Alliance-$8.64B-$7.29N/A8.211.42-4.07%17.66%2.22%N/ALatest TEVA, JNJ, CVS, WBA, and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026CVSCVS Health$2.21$2.57+$0.36$2.30$94.99 billion$100.43 billion5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion4/29/2026Q1 2026TEVATeva Pharmaceutical Industries$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion3/31/2026Q1 2026NVONovo Nordisk A/SN/A$1.0270N/A$1.69N/A$10.85 billion3/31/2026Q1 2026TEVATeva Pharmaceutical IndustriesN/A$0.53N/A$0.31N/A$3.98 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVSCVS Health$2.662.85%+5.87%117.18%4 YearsJNJJohnson & Johnson$5.202.22%+5.25%60.12%64 YearsNVONovo Nordisk A/S$1.753.90%+21.74%41.08%N/ATEVATeva Pharmaceutical IndustriesN/AN/AN/AN/AN/AWBAWalgreens Boots AllianceN/AN/AN/AN/AN/ALatest TEVA, JNJ, CVS, WBA, and NVO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/20263/18/2026CVSCVS Healthquarterly$0.66503.37%4/23/20264/23/20265/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSCVS Health0.780.870.66JNJJohnson & Johnson0.461.030.77NVONovo Nordisk A/S0.590.790.56TEVATeva Pharmaceutical Industries1.701.010.78WBAWalgreens Boots Alliance0.960.600.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSCVS Health80.66%JNJJohnson & Johnson69.55%NVONovo Nordisk A/S11.54%TEVATeva Pharmaceutical Industries54.05%WBAWalgreens Boots Alliance58.59%Insider OwnershipCompanyInsider OwnershipCVSCVS Health0.85%JNJJohnson & Johnson0.16%NVONovo Nordisk A/S0.07%TEVATeva Pharmaceutical Industries0.54%WBAWalgreens Boots Alliance17.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSCVS Health300,0001.28 billion1.27 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableTEVATeva Pharmaceutical Industries33,9501.15 billion1.14 billionOptionableWBAWalgreens Boots Alliance325,000865.56 million714.09 millionOptionableTEVA, JNJ, CVS, WBA, and NVO HeadlinesRecent News About These CompaniesThis Former Dividend King Just Agreed to Be Bought Out.April 13, 2026 | 247wallst.comStefano Pessina vows to rebuild ‘all the value’ lost at his Boots empireApril 7, 2026 | ft.comClark Howard: $200 Walgreens Quote Became $22 at Cost Plus Drugs for This NC ManApril 3, 2026 | 247wallst.comWalgreens Targets $4 Billion EBITDA Under Sycamore's Turnaround PlanApril 2, 2026 | finance.yahoo.comWalgreens Brings Hybrid Pharmacy Program to 6 StatesMarch 2, 2026 | pymnts.comWalgreens Brings Hybrid Pharmacy Program to 6 StatesMarch 2, 2026 | pymnts.comWalgreens Virtual Healthcare Adds Weight Management Services to Support Patients on Their Weight Loss JourneyFebruary 26, 2026 | businesswire.comWalgreens to close Texas distribution center in streamlining effortFebruary 25, 2026 | finance.yahoo.comWalgreens to lay off hundreds across two statesFebruary 23, 2026 | healthcarefinancenews.comHWalgreens is laying off hundreds of workers, but its list of store closures in 2026 might not be as big as fearedFebruary 20, 2026 | fastcompany.comFWalgreens cuts workforce after private equity buyout, Bloomberg News reportsFebruary 19, 2026 | reuters.comHere are the retailers with the most store openings and closures planned for 2026February 2, 2026 | cnbc.comBoots Group CEO to retire from role and become chairpersonJanuary 27, 2026 | theretailbulletin.comTWalgreens Supporting Patients, Customers and Communities Ahead of Approaching Winter StormsJanuary 22, 2026 | businesswire.comWalgreens Launches Pharmacy Patient Advisory Board to Strengthen Patient CollaborationNovember 6, 2025 | businesswire.comWalgreens Boots Alliance Goes Private in Landmark $10 Billion AcquisitionNovember 4, 2025 | aktiencheck.deAWalgreens Launches Enhanced Respiratory Index to Track Flu and COVID-19 HotspotsNovember 4, 2025 | businesswire.comAmneal Launches Brekiya® Autoinjector for Treatment of Migraines and Cluster Headaches Available Exclusively at Walgreens Specialty Pharmacy and Sterling Specialty PharmacyOctober 27, 2025 | quiverquant.comQAmneal Launches Brekiya® â the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster HeadachesOctober 27, 2025 | markets.businessinsider.comBoots’ biggest problem might just be its billionaire ownerSeptember 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026TEVA, JNJ, CVS, WBA, and NVO Company DescriptionsCVS Health NYSE:CVS$93.24 -0.02 (-0.02%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$93.61 +0.37 (+0.40%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.Johnson & Johnson NYSE:JNJ$234.67 +0.33 (+0.14%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$234.43 -0.25 (-0.10%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novo Nordisk A/S NYSE:NVO$44.91 -0.05 (-0.11%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$44.90 -0.01 (-0.03%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Teva Pharmaceutical Industries NYSE:TEVA$34.03 -0.04 (-0.10%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$34.08 +0.05 (+0.15%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.Walgreens Boots Alliance NASDAQ:WBAWalgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
